Bullish Prospects Lining Up for Viaderma Inc (OTCMKTS:VDRM)


Viaderma Inc (OTCMKTS:VDRM) shares were up 34.62% to $0.00350 and flat in after-hours trading. Share prices have been trading in a 52-week range of $0.00 to $0.02. The company has a market cap of $552K at 200.32 million shares outstanding.

In a press release this week, Viaderma Inc shared that several patients have had significant treatment success with the use of its innovative transdermal system for the delivery of its FDA registered drug, Viabecline. This is a topical liquid tetracycline-based antibiotic that uses a patent-pending innovative transdermal delivery system that can convert oral medication active ingredients into topical drugs and is registered as a first aid antibiotic to help prevent skin infection in minor cuts, scrapes, and burns.

The results were achieved in just 10 days of treatment using the company’s proprietary patent-pending transdermal delivery system, which can deliver medications and nutrients into the body through the skin and increase the absorption as much as 100 times directly to the localized treatment areas.

“We are also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido,” said Viaderma Inc CEO Dr. Christopher Otiko. “We are enthusiastic about the results we have achieved to date in terms of the anecdotal feedback we have received from the medical community. We are also in early-stage discussion with two companies to private label Viabecline for distribution in the Middle East, Asia and North Africa, and Europe.”

The company is also seeking to venture in the cannabis industry, which is set to reach $20 billion by 2020 thanks to the outcome of the November 8 vote to legalize the use of medical or recreational marijuana in several states. The company announced the Patent Pending use of its innovative transdermal system for the delivery of Calanoids and Tetrahydrocannabinol for the treatment of several diseases.

With that, the company has several potential revenue streams lined up and the commercialization of its products could lend tremendous upside to share prices. CBD is often used for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn’s disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis and the addition of transdermal delivery can spur immediate absorption into the bloodstream.

Viaderma Inc is a pharmaceutical company focused on bringing new products to the pharmaceutical industry through research and development. With that, it licenses and sells products in fields of medicine ranging from infectious diseases to stem-cell therapy. The company’s products are distributed over-the-counter and are applied topically using a delivery system technology.

Aside from developing and selling new products to the market, Viaderma Inc is exploring the possibility of licensing the technology to other pharmaceutical companies. It has products in development in various fields, including topical antibiotics (TetraStem), topical anti-viral product (Viralcur) for genital herpes, anti-fungal products for onychomycocis (OnyPro), hair loss prevention product (HairGain), skin cancer therapies (Cantrile), and a topical stem cell therapy product (TetraStem Plus).